HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

• Status: NOT_YET_RECRUITING
• Trial end date: 2032-10-01

Summary

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol E is a phase I/II trial evaluating the safety and efficacy of capivasertib + venetocolax in combination with dexamethasone in children and AYA with R/R ped ALL/LBL whose tumor present with alterations of the PAM pathway, or lacking any mutations.

• Phase: PHASE1

Details

• Lead Sponsor: Princess Maxima Center for Pediatric Oncology
• Collaborators: AbbVie; AstraZeneca
• Treatments: capivasertib; venetoclax